ProKidney 10-Q: $141.9M Cash Won't Fund 12 Months, Going Concern Doubt
PROK sits 32% above its 52-week low of $0.87.
Summary
ProKidney's Q3 10-Q shows $141.9M of cash and securities, a formal going-concern warning, and a nine-month operating burn of $120.7M, with a fresh $200M at-the-market program as the funding backstop.
Key Events · Earnings and Guidance · PROK
-
Going Concern Doubt Disclosed
Management concluded that existing cash and marketable securities of $141,864,000 at September 30, 2026 will not fund obligations for the 12 months following the filing, and added a going-concern risk factor.
-
Cash Burn Accelerates
Operating cash use was $120.7M for nine months versus $87.6M a year earlier; cash and equivalents fell to $81.4M from $108.5M at December 31, 2025.
-
R&D Spend Jumps on PROACT 1
Q3 research and development expense rose to $40.8M from $26.8M, driving a net loss available to Class A holders of $35.6M for the quarter and $84.1M for nine months.
-
$200M ATM Is the Funding Backstop
The October 29, 2026 Jefferies at-the-market agreement allows up to $200M of Class A stock sales; no shares have been sold under it, and the prior 2025 agreement terminates November 23, 2026.
Analysis · PROK · Life Sciences
ProKidney closed Q3 2026 with $141.9M in cash and marketable securities, and management now says that is not enough to fund obligations for the 12 months after this filing — a formal going-concern conclusion and a new risk factor. The burn is accelerating: operating cash use was $120.7M over nine months versus $87.6M a year earlier, and R&D jumped to $40.8M in Q3 from $26.8M as the Phase 3 PROACT 1 trial enrolls. The company's answer is the $200M Jefferies at-the-market program set up October 29, 2026, which is pure dilution if drawn. The offset is clinical: full enrollment in PROACT 1 is expected in Q1 2027 and the surrogate eGFR-slope topline in Q2 2027 — the data that would justify financing the company at all.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PROK was trading at $1.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $347.7M. The 52-week trading range was $0.87 to $2.88. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.